Intensive studies demonstrated that HIF2α, but not HIF1α, play a vital role in ccRCC progression (Kaelin, 2022); Consequently, HIF2α inhibitors, including PT2385, have been developed and used in clinical trials for ccRCC treatment (Chen et al, 2016; Courtney et al, 2018; Wallace et al, 2016). This evidence concerns the gene HIF1A and nonpapillary renal cell carcinoma.